Shukui Qin
Nanjing Tianyinshan Hospital · Chinese People's Liberation Army Eastern Theater General Hospital Qinhuai medical District · Shanghai East Hospital of Tongji University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shukui Qin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:41 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT06361888 · A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerHutchmed · recruiting · Metastatic Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT06239155 · A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsAscentawits Pharmaceuticals, Ltd · active not recruiting · Advanced Solid Tumors, Hepatocellular Carcinoma · principal investigator
- Ph2/Ph3NCT05976568 · A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaQilu Pharmaceutical Co., Ltd. · not yet recruiting · Hepatocellular Carcinoma · principal investigator
- Ph3NCT04914598 · A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural EffusionsJiangsu Simcere Pharmaceutical Co., Ltd. · active not recruiting · Malignant Pleural Effusion · study chair
- Ph1/Ph2NCT04503902 · Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular CarcinomaSuzhou Zelgen Biopharmaceuticals Co.,Ltd · unknown · Advanced Hepatocellular Carcinoma · principal investigator
- Ph2/Ph3NCT04183478 · The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic CancerRenJi Hospital · unknown · Pancreatic Cancer · principal investigator
- Ph3NCT03967327 · A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer PainMundipharma (China) Pharmaceutical Co. Ltd · unknown · Cancer Pain · principal investigator
- Ph3NCT03764293 · A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCJiangsu HengRui Medicine Co., Ltd. · completed · Locally Advanced or Metastatic and Unresectable HCC · principal investigator
- N/ANCT03631459 · A Multicenter Real World Study of Kanglaite for Cancer CachexiaZhejiang Kanglaite Pharmaceutical Co.Ltd · unknown · Cancer Cachexia · principal investigator
- Ph3NCT03478488 · Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC3D Medicines (Sichuan) Co., Ltd. · completed · Biliary Tract Neoplasms · principal investigator
- Ph3NCT03236649 · The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsBeijing Shenogen Biomedical Co., Ltd · terminated · Hepatocellular Carcinoma (HCC) · principal investigator
- Ph3NCT03236636 · The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsBeijing Shenogen Biomedical Co., Ltd · unknown · Advanced HBV-Related Hepatocellular Carcinoma (HCC) · principal investigator
- Ph2/Ph3NCT02645981 · Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular CarcinomaSuzhou Zelgen Biopharmaceuticals Co.,Ltd · completed · HCC · study chair
- Ph3NCT02395016 · A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic CancerBiotech Pharmaceutical Co., Ltd. · completed · Pancreatic Cancer · principal investigator
- Ph2NCT01972672 · The Phase II Study of Icaritin in Patients With Advanced Hepatocellular CarcinomaBeijing Shenogen Biomedical Co., Ltd · completed · Hepatocellular Carcinoma (HCC) · principal investigator
- Ph3NCT01937156 · A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and VomitingSolasia Pharma K.K. · completed · Chemotherapy-induced Nausea and Vomiting · principal investigator
- Ph3NCT01512745 · Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerJiangsu HengRui Medicine Co., Ltd. · completed · Advanced or Metastatic Gastric Cancer · principal investigator
- Ph2NCT01327235 · Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or AscitesJiangsu Simcere Pharmaceutical Co., Ltd. · completed · Malignant Pleural Effusion, Malignant Ascites · principal investigator
- Ph2NCT01192971 · A Study of Apatinib in Patients With Advanced Hepatocellular CarcinomaJiangsu HengRui Medicine Co., Ltd. · completed · Advanced Hepatocellular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:41 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020182 citationsRCR 7.2
- Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020176 citationsRCR 6.8
- Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.J Clin Oncol · 202363 citationsRCR 4.8
- Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.Signal Transduct Target Ther · 202420 citationsRCR 2.4
- Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).Eur J Cancer · 20256 citationsRCR 1.7
- Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial.Signal Transduct Target Ther · 20256 citationsRCR 1.4